Significant Ownership of Caligan Partners LP

Signature - Title
/s/ David Johnson - David Johnson, Managing Partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Caligan Partners LP.

Notify me when Caligan Partners LP files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Caligan Partners LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VRCA Verrica Pharmaceuticals Inc. Common Stock, par value $0.0001 per share 10% $43,635,492 6,503,054 0% Caligan Partners LP 26 Dec 2025
VRCA Verrica Pharmaceuticals Inc. Common stock, $0.0001 par value per share 10% $7,769,760 15,856,653 Caligan Partners LP 31 Dec 2024
ANIK Anika Therapeutics, Inc. Common Stock, par value $0.01 per share 10% $13,791,743 1,435,130 0% Caligan Partners LP 23 Jan 2026
AVTX Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share 4.9% $14,941,984 +$816,990 881,533 +5.8% Caligan Partners LP 31 Dec 2025
EOLS Evolus, Inc. Common Stock, par value $0.00001 per share 0% $0 -$23,385,028 0 -100% Caligan Partners LP 31 Dec 2025
YMAB Y-mAbs Therapeutics, Inc. Common stock, par value $0.0001 per share 0% $0 -$20,169,863 0 -100% Caligan Partners LP 30 Sep 2025

Schedules 13D/G Reported by Caligan Partners LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.